XClose

UCL Division of Biosciences

Home
Menu

Aamir Ahmed and Chris Thrasivoulou awarded patent for ground-breaking drug repurposing therapy

27 January 2022

Drs Aamir Ahmed (KCL Prostate Cancer Research Centre) and Dr Christopher Thrasivoulou (UCL Cell and Developmental Biology) have been awarded a patent by the EPO for their ground-breaking drug repurposing therapy for epithelial cancers such as breast and prostate.

A convergent model for the canonical (Wnt/β-catenin) and non-canonical (Wnt/Ca2+) Wnt signaling, in mammalian cell lines

Drs Aamir Ahmed (Prostate Cancer Research Centre, KCL Division of Surgery) and Christopher Thrasivoulou (UCL Cell and Developmental Biology) have been awarded a patent by the EPO for their ground-breaking drug repurposing therapy for epithelial cancers such as breast and prostate (European Patent No. 3060204). These cancers cause hundreds of thousands of deaths worldwide and are a significant cost burden for the NHS. Evidence based drug repurposing, use of drugs that are indicated for diseases other than cancer, can offer both clinical and cost-effective therapy for devastating diseases such as cancer. Another key advantage of such therapies is limited and known side effects, unlike the severe side effects of current cancer therapies.

Links:

https://worldwide.espacenet.com/patent/search/family/049727160/publication/EP3060204A2?q=3060204

https://www.jbc.org/article/S0021-9258(19)54289-2/fulltext

Image: A convergent model for the canonical (Wnt/β-catenin) and non-canonical (Wnt/Ca2+) Wnt signaling, in mammalian cell lines. Thrasivoulou, Millar & Ahmed.